The uPA receptor and the somatomedin B region of vitronectin direct the localization of uPA to focal adhesions in microvessel endothelial cells

Matrix Biology

Volumn 26, Issue 5, 2007, Pages 359-370

  Salasznyk, Roman M ^a   Zappala, Maria ^a   Zheng, Mingzhe ^a   Yu, Lin ^a   Wilkins Port, Cynthia ^a   McKeown Longo, Paula J ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

Author keywords

Focal adhesions; Integrin; Plasminogen activator receptor; Urokinase; Vitronectin

Indexed keywords

INTEGRIN RECEPTOR; PHOSPHOLIPASE C; SOMATOMEDIN B; UROKINASE; VITRONECTIN;

ARTICLE; BINDING SITE; CELL ADHESION; CELL MIGRATION; CONTROLLED STUDY; ENDOTHELIUM CELL; FOCAL ADHESION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MICROVASCULATURE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN LOCALIZATION;

ADULT; CELL CULTURE TECHNIQUES; CELLS, CULTURED; ENDOTHELIUM; ENDOTHELIUM, VASCULAR; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; FOCAL ADHESIONS; HUMANS; MICROSCOPY, FLUORESCENCE; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, CELL SURFACE; RECOMBINANT FUSION PROTEINS; SKIN; SOMATOMEDINS; URINARY PLASMINOGEN ACTIVATOR; VITRONECTIN;

EID: 34249035764     PISSN: 0945053X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.matbio.2007.01.009     Document Type: Article

References (45)

1. Aguirre-Ghiso J.A., Kovalski K., and Ossowski L. Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. J. Cell Biol. 147 (1999) 89-104
2. Ahmed N., Oliva K., Wang Y., Quinn M., and Rice G. Downregulation of urokinase plasminogen activator receptor expression inhibits ERK signalling with concomitant suppression of invasiveness due to loss of uPAR-β1 integrin complex in colon cancer cells. Br. J. Cancer 89 (2003) 374-384
3. Cao D.J., Guo Y.L., and Colman R.W. Urokinase-type plasminogen activator receptor is involved in mediating the apoptotic effect of cleaved high molecular weight kininogen in human endothelial cells. Circ. Res. 94 (2004) 1227-1234
4. Carlin S.M., Resink T.J., Tamm M., and Roth M. Urokinase signal transduction and its role in cell migration. FASEB J. 19 (2005) 195-202
5. Ciambrone G.J., and McKeown-Longo P.J. Plasminogen activator inhibitor type 1 stabilizes vitronectin-dependent adhesions in HT-1080 cells. J. Cell Biol. 111 (1990) 2183-2195
6. Ciambrone G.J., and McKeown-Longo P.J. Vitronectin regulates the synthesis and localization of urokinase-type plasminogen activator in HT-1080 cells. J. Biol. Chem. 267 (1992) 13617-13622
7. Degryse B., Resnati M., Czekay R.-P., Loskutoff D.J., and Blasi F. Domain 2 of the urokinase receptor contains an integrin-interacting epitope with intrinsic signaling activity: generation of a new integrin inhibitor. J. Biol. Chem. 280 (2005) 24792-24803
8. Deng G., Curriden S.A., Wang S., Rosenberg S., and Loskutoff D.J. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release?. J. Cell Biol. 134 (1996) 1563-1571
9. Deng G., Curriden S.A., Hu G., Czekay R.P., and Loskutoff D.J. Plasminogen activator inhibitor-1 regulates cell adhesion by binding to the somatomedin B domain of vitronectin. J. Cell Physiol. 189 (2001) 23-33
10. Edwards S., Lalor P.F., Tuncer C., and Adams D.H. Vitronectin in human hepatic tumours contributes to the recruitment of lymphocytes in an αvβ3-independent manner. Br. J. Cancer 95 11 (2006) 1545-1554
11. Eming S.A., and Krieg T. Molecular mechanisms of VEGF-A action during tissue repair. J. Invest. Dermatol. 126 (2006) 79-86 (Suppl.)
12. Fibbi G., Caldini R., Chevanne M., Pucci M., Schiavone N., Morbidelli L., Parenti A., Granger H.J., Del Rosso M., and Ziche M. Urokinase-dependent angiogenesis in vitro and diacylglycerol production are blocked by antisense oligonucleotides against the urokinase receptor. Lab. Invest. 78 (1998) 1109-1119
13. 5 integrin. J. Cell Sci. 119 (2006) 3424-3434
14. Gargiulo L., Longanesi-Cattani I., Bifulco K., Franco P., Raiola R., Campiglia P., Grieco P., Peluso G., Stoppelli M.P., and Carriero M.V. Cross-talk between fMLP and vitronectin receptors triggered by urokinase receptor-derived SRSRY peptide. J. Biol. Chem. 280 (2005) 25225-25232
15. 1 integrin association in proteinase regulatory pathways. J. Biol. Chem. 281 (2006) 13021-13029
16. Gladson C.L., Wilcox J.N., Sanders L., Gillespie G.Y., and Cheresh D.A. Cerebral microenvironment influences expression of the vitronectin gene in astrocytic tumors. J. Cell Sci. 108 (1995) 947-956
17. Hocking D.C., Sottile J., Reho T., Fassler R., and McKeown-Longo P.J. Inhibition of fibronectin matrix assembly by the heparin-binding domain of vitronectin. J. Biol. Chem. 274 (1999) 27257-27264
18. Jurasz P., Santos-Martinez M.J., Radomska A., and Radomski M.W. Generation of platelet angiostatin mediated by urokinase plasminogen activator: effects on angiogenesis. J. Thromb. Haemost. 4 (2006) 1095-1106
19. Kanse S.M., Kost C., Wilhelm O.G., Andreasen P.A., and Preissner K.T. The urokinase receptor is a major vitronectin-binding protein on endothelial cells. Exp. Cell Res. 224 (1996) 344-353
20. Kanse S.M., Chavakis T., Al-Fakhri N., Hersemeyer K., Monard D., and Preissner K.T. Reciprocal regulation of urokinase receptor (CD87)-mediated cell adhesion by plasminogen activator inhibitor-1 and protease nexin-1. J. Cell Sci. 117 (2004) 477-485
21. Kjoller L., and Hall A. Rac mediates cytoskeletal rearrangements and increased cell motility induced by urokinase-type plasminogen activator receptor binding to vitronectin. J. Cell Biol. 152 (2001) 1145-1158
22. Kondoh N., Wakatsuki T., Ryo A., Hada A., Aihara T., Horiuchi S., Goseki N., Matsubara O., Takenaka K., Shichita M., Tanaka K., Shuda M., and Yamamoto M. Identification and characterization of genes associated with human hepatocellular carcinogenesis. Cancer Res. 59 (1999) 4990-4996
23. Liang O.D., Chavakis T., Kanse S.M., and Preissner K.T. Ligand binding regions in the receptor for urokinase-type plasminogen activator. J. Biol. Chem. 276 (2001) 28946-28953
24. Lu H., Mabilat C., Yeh P., Guitton J., Li H., Pouchelet M., Shoevaert D., Legrand Y., Soria J., and Soria C. Blockage of urokinase receptor reduces in vitro the motility and the deformability of endothelial cells. FEBS Lett. 380 (1996) 21-24
25. Mazzieri R., D'Alessio S., Kenmoe R.K., Ossowski L., and Blasi F. An uncleavable uPAR mutant allows dissection of signaling pathways in uPA-dependent cell migration. Mol. Biol. Cell 17 (2006) 367-378
26. Min H.Y., Doyle L.V., Vitt C.R., Zandonella C.L., Stratton-Thomas J.R., Shuman M.A., and Rosenberg S. Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngenetic mice. Cancer Res. 56 (1996) 2428-2433
27. Mould A.P., Barton S.J., Askari J.A., McEwan P.A., Buckley P.A., Craig S.E., and Humphries M.J. Conformational changes in the integrin βA domain provide a mechanism for signal transduction via hybrid domain movement. J. Biol. Chem. 278 (2003) 17028-17035
28. Nguyen D.H., Catling A.D., Webb D.J., Sankovic M., Walker L.A., Somlyo A.V., Weber M.J., and Gonias S.L. Myosin light chain kinase functions downstream of Ras ERK to promote migration of urokinase-type plasminogen activator-stimulated cells in an integrin-selective manner. J. Cell. Biol. 146 (1999) 149-164
29. Okumura Y., Kamikubo Y., Curriden S.A., Wang J., Kiwada T., Futaki S., Kitagawa K., and Loskutoff D.J. Kinetic analysis of the interaction between vitronectin and the urokinase receptor. J. Biol. Chem. 277 (2002) 9395-9404
30. Pendurthi U.R., Tran T.T., Post M., and Rao L.V. Proteolysis of CCN1 by plasmin: functional implications. Cancer Res. 65 (2005) 9705-9711
31. Prager G.W., Breuss J.M., Steurer S., Olcaydu D., Mihaly J., Brunner P.M., Stockinger H., and Binder B.R. Vascular endothelial growth factor receptor-2-induced initial endothelial cell migration depends on the presence of the urokinase receptor. Circ. Res. 94 (2004) 1562-1570
32. Roth D., Piekarek M., Paulsson M., Christ H., Krieg T., Bloch W., Davidson J.M., and Eming S.A. Plasmin modulates vascular endothelial growth factor-A-mediated angiogenesis during wound repair. Am. J. Pathol. 168 (2006) 670-684
33. Seiffert D., and Smith J.W. The cell adhesion domain in plasma vitronectin is cryptic. J. Biol. Chem. 272 (1997) 13705-13710
34. Sidenius N., Andolfo A., Fesce R., and Blasi F. Urokinase regulates vitronectin binding by controlling urokinase receptor oligomerization. J. Biol. Chem. 277 (2002) 27982-27990
35. Simon D.I., Weis Y., Zhang L., Rao N.K., Xu H., Chen Z., Liu Q., Rosenberg S., and Chapman H.A. Identification of a urokinase receptor-integrin interaction site. J. Biol. Chem. 275 (2000) 10228-10234
36. van der Pluijm G., Sijmons B., Vloedgraven H., van der Bent C., Drijfhout J.W., Verheijen J., Quax P., Karperien M., Papapoulos S., and Lowik C. Urokinase-receptor/integrin complexes are functionally involved in adhesion and progression of human breast cancer in vivo. Am. J. Pathol. 159 (2001) 971-982
37. Waltz D.A., Natkin L.R., Fujita R.M., Wei Y., and Chapman H.A. Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin. J. Clin. Invest. 100 (1997) 58-67
38. Wei Y., Lukashev M., Simon D.I., Bodary S.C., Rosenberg S., Doyle M.V., and Chapman H.A. Regulation of integrin function by the urokinase receptor. Science 273 (1996) 1551-1555
39. 1. Mol. Biol. Cell 12 (2001) 2975-2986
40. Wilcox S.A., Reho T., Higgins P.J., Tominna-Sebald E., and McKeown-Longo P.J. Localization of urokinase to focal adhesions by human fibrosarcoma cells synthesizing recombinant vitronectin. Biochem. Cell. Biol. 74 (1996) 899-910
41. Wilcox-Adelman S.A., Wilkins-Port C.E., and McKeown-Longo P.J. Localization of urokinase type plasminogen activator to focal adhesions requires ligation of vitronectin integrin receptors. Cell Adhes. Commun. 7 (2000) 477-490
42. Wilkins-Port C.E., Sanderson R.D., Tominna-Sebald E., and McKeown-Longo P.J. Vitronectin's basic domain is a syndecan ligand which functions in trans to regulate vitronectin turnover. Cell Commun. Adhes. 10 (2003) 85-103
43. Wong W.S.F., Simon D.I., Rosoff P.M., Rao N.K., and Chapman H.A. Mechanisms of pertussis toxin-induced myelomonocytic cell adhesion: role of Mac-1 (CD11b/CD18) and urokinase receptor (CD87). Immunology 88 (1996) 90-97
44. Yatohgo T., Izumi M., Kashiwagi H., and Hayashi M. Novel purification of vitronectin from human plasma by heparin affinity chromatography. Cell Struct. Funct. 13 (1988) 281-292
45. Zheng M., and McKeown-Longo P.J. Regulation of HEF1 expression and phosphorylation by TGF-β1 and cell adhesion. J. Biol. Chem. 277 (2002) 39599-39608